should i microdose glp-1 microdosing is popular, but there's little evidence it works Exploring Microdosing GLP-1 Medications: Benefits

Answer : The major players operating in the Australia GLP-1 receptor agonist market are AstraZeneca PLC, Biocon, Eli Lilly and Co, Novo Nordisk A/S ADR, Sanofi SA, and Others

In simple obesity (body mass index = 30.034.9 kg/m2), the annual probability of attaining normal weight was 1 in 210 for men and 1 in 124 for women , increasing to 1 in 1290 for men and 1 in 677 for women with morbid obesity (body mass index = 40.044.9 kg/m2)

This may include prescription medication, but it doesnt have to include prescription medication

Li AQ, Zhao L, Zhou TF, Zhang MQ, Qin XM

Retatrutide, with its triple action on GLP-1, GIP, and glucagon receptors, is the most advanced example yet